David J. Endicott
CIK 1532133 · Pres., Hospira Medical Devices · last filed 2017-07-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
4
Total Filings
19
Lifetime Open-Market Net
-$7.62M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | — | — | — | $0 | 6 | 2017-07-18 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | Director | 0 | — | — | $0 | 3 | 2017-04-28 |
| HOSPIRA INC (HSP) Delisted | Pres., Hospira Medical Devices | 205,668 | — | — | $0 | 2 | 2015-09-03 |
| ALLERGAN INC (AGN) Delisted | CVP and President, AGN Med | 20,448 | — | — | -$7.62M | 7 | 2013-02-22 |
Recent Filings · Page 2 of 2
19 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-06-07 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-02-22 | ALLERGAN INC (AGN) Delisted | Mixed | −2,794 | -$302.0K | EDGAR |
| 2013-02-20 | ALLERGAN INC (AGN) Delisted | Tax (F) | −225 | -$24.3K | EDGAR |
| 2013-01-23 | ALLERGAN INC (AGN) Delisted | Mixed | — | -$54.0K | EDGAR |
| 2012-11-30 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-11-30 | ALLERGAN INC (AGN) Delisted | Mixed | — | -$1.47M | EDGAR |
| 2012-05-09 | ALLERGAN INC (AGN) Delisted | Mixed | — | -$1.24M | EDGAR |
| 2012-02-24 | ALLERGAN INC (AGN) Delisted | Tax (F) | −212 | -$18.5K | EDGAR |
| 2012-02-22 | ALLERGAN INC (AGN) Delisted | Grant (A) | +378 | $0 | EDGAR |
Showing 11–19 of 19
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.